Abstract: Objective To investigate the effect of cerebroprotein hydrolysate on the serum high sensitivity C reactive protein (hsCRP), insulin-like growth factor-1 (IGF-1) and interleukin-18 (IL-18) in patients with hypoxic ischemic encephalopathy (HIE) in plateau region. Methods From January, 2013 to May, 2015, 104 cases with neonatal HIE in our department were randomly divided into conventional treatment group (n=52) and cerebroprotein hydrolysate group (n=52). Besides, 35 cases of healthy newborn were chosen as the control group. The total effective rate and the serum hsCRP, IGF-1, IL-18 levels were compared. Results The IGF-1 level was lower, and the levels of hsCRP and IL-18 were higher in moderate HIE group and severe HIE group than in the control group and the mild HIE group, respectively (P<0.05). The efficiency rate was significantly higher in the cerebroprotein hydrolysate group than in the conventional treatment group (χ2= 8.922, P=0.012). Compared with the conventional treatment group, the IGF-1 level increased, and the levels of hsCRP and IL-18 decreased in the cerebroprotein hydrolysate group (P<0.05). Conclusion Cerebroprotein hydrolysate is effective on patients with HIE in plateau region. The changes of serum hsCRP, IGF-1, and IL-18 levels can be used as auxiliary indexes for early diagnosis of HIE.

Key words: newborn, hypoxic ischemic encephalopathy, cerebroprotein hydrolysate, high sensitivity C reactive protein, insulin- like growth factor-1, interleukin-18